⌘K
OverviewStock screenerAnalyst actionsCalendar
MarketsInvestorsSign in
StockUnited StatesNasdaqGS

INCY

Incyte Corporation

Healthcare · Biotechnology

126.01USD

+1.6100 (+1.29%)

DescriptionHistoricalFinancialsRelative ValueResearchNewsDiscussionOptionsPrice Chart ↗Fundamental Chart ↗
ProfileRatiosRevenue & EPS
Reading financial statements from SEC filings…
A first visit to a security takes a few seconds.
1)

Comparable Revenue

EM »

Revenue

 

 

QuarterlyAnnual
Reported
(USD)202220232024202520262027
FY3.4B3.7B4.2B5.1B5.9B6.3B
Q1733.2M808.7M880.9M1.1B1.3B—
Q2911.4M954.6M1.0B1.2B——
Q3823.3M919.0M1.1B1.4B1.5B—
Q4926.7M*1.0B*1.2B*1.5B*1.5B—
2)

Comparable Earnings Per Share

EM »

Revenue

 

 

QuarterlyAnnual
Reported
(USD)202220232024202520262027
FY1.522.65.1506.413.468.89
Q1.170.100.750.8001.47—
Q2.720.900-2.042.04——
Q3.500.760.5402.11-3.47—
Q4.127*

Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.

.890*
.956*
1.49*
1.95
—